Cover Image
市場調查報告書

精神醫學相關的各種合作契約:契約條件・合意內容

Global Psychiatry Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 238157
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
精神醫學相關的各種合作契約:契約條件・合意內容 Global Psychiatry Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告,調查分析精神醫學相關的各種合作契約,彙整近幾年各種契約的動向、大型契約以及大型醫藥品業者的契約概要、契約區分・開發階段・技術區分・適應症區分別的名錄等,由下列摘要形式闡述。

報告摘要

第1章 簡介

第2章 精神醫學相關的各種契約動向

  • 簡介
  • 過去數年的精神醫學相關合作
  • 大型藥廠的契約活動
  • 對精神醫學相關事業不積極的大型藥廠
  • 精神醫學相關合作:契約類型別
  • 精神醫學相關合作:產業部門別
  • 精神醫學相關合作:開發階段別
  • 精神醫學相關合作:技術種類別
  • 平均契約期間
  • 預付款
  • 目標達成報酬
  • 專利費用,等

第3章 主要契約

  • 簡介
  • 主要契約:交易額別
  • 大型藥廠所涉及的主要契約

第4章 大型藥廠的契約

  • 企業檔案資料

第5章 契約名錄

  • 簡介
  • 企業別:A-Z
  • 契約類型別
    • 資產購買
    • 大型的委外授權
    • 共同開發
    • 共同R&D
    • 服務契約
    • 共同促銷
    • CRADA
    • 開發
    • 批發銷售
    • 評價
    • 讓與
    • 合資企業
    • 授權
    • 製造
    • 市場行銷
    • 材料移轉
    • 選項
    • 促銷
    • 研究
    • 和解相關
    • 資產分割
    • 供給
    • 技術移轉
  • 開發階段別
    • 藥物設計
    • 前臨床
    • 階段I
    • 階段II
    • 階段III
    • 申請登錄
    • 市售
  • 技術種類別
    • 佐劑
    • 解析
    • 動物模型
    • 分析
    • 生物防禦
    • 生物資訊學
    • 生物學化合物
    • 生物標記
    • 生物材料
    • 生物製程
    • 生物仿製藥/bio-better
    • 血液製劑
    • 細胞培養
    • 細胞治療
    • 臨床檢查
    • 診斷(搭配診斷)
    • 裝置
    • 診斷
    • 藥物設計工具
    • DNA探針
    • 藥物傳遞
    • 實現技術
    • 表觀遺傳學
    • 機器
    • 設備
    • 基因治療
    • 基因體學
    • 醣組學
    • 顯影
    • 植入
    • 體外模式
    • 微陣列
    • 單株抗體奈米科技,等
  • 適應症別
    • 精神病
    • 不安障礙
    • 全身性不安障礙
    • 精神障礙
    • PTSD
    • 注意欠缺多動障礙
    • 双極性障礙
    • 慢性疲勞症候群
    • 認知障礙
    • 癡呆
    • 阿茲海默症
    • Lewy小體型癡呆
    • 自閉症
    • 躁鬱症
    • 強迫性障礙
    • 精神分裂
    • 睡眠障礙

第6章 合作機會

  • 線上合作
  • 合作活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2204

The ‘Global Psychiatry Partnering 2010-2016: Deal trends, players and financials ’report provides comprehensive understanding and unprecedented access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Psychiatry Partnering 2010 to 2016’ provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Psychiatry partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Psychiatry partnering agreement structure
  • Psychiatry partnering contract documents
  • Top Psychiatry deals by value
  • Most active Psychiatry dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Psychiatry deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Psychiatry deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2010. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report scope

‘Global Psychiatry Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Psychiatry trends and structure of deals entered into by leading companies worldwide.

‘Global Psychiatry Partnering 2010 to 2016’ includes:

  • Trends in Psychiatry dealmaking in the biopharma industry since 2010
  • Analysis of Psychiatry deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Psychiatry deal contract documents
  • Comprehensive access to over 3500 Psychiatry deal records
  • The leading Psychiatry deals by value since 2010
  • Most active Psychiatry dealmakers since 2010

The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

In ‘Global Psychiatry Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Psychiatry Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 600 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Psychiatry Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Psychiatry deal trends since 2010
  • Access Psychiatry deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Psychiatry partner companies
  • Comprehensive access to over 750 links to actual Psychiatry deals entered into by the world's biopharma companies
  • Indepth review of Psychiatry deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Psychiatry opportunities
  • Uncover companies actively partnering Psychiatry opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Psychiatry dealmaking

  • 2.1. Introduction
  • 2.2. Psychiatry partnering over the years
  • 2.3. Psychiatry partnering by deal type
  • 2.4. Psychiatry partnering by industry sector
  • 2.5. Psychiatry partnering by stage of development
  • 2.6. Psychiatry partnering by technology type
  • 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 -Financial deal terms for Psychiatry partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Psychiatry partnering
  • 3.3. Psychiatry partnering headline values
  • 3.4. Psychiatry deal upfront payments
  • 3.5. Psychiatry deal milestone payments
  • 3.6. Psychiatry royalty rates

Chapter 4 - Leading Psychiatry deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Psychiatry partnering
  • 4.3. List of most active dealmakers in Psychiatry
  • 4.4. Top Psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

  • 5.1. Introduction
  • 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Psychiatry therapeutic target

Appendices

  • Appendix 1 - Directory of Psychiatry deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Psychiatry deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Psychiatry deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Psychiatry deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Psychiatry partnering since 2010
  • Figure 2: Psychiatry partnering by deal type since 2010
  • Figure 3: Psychiatry partnering by industry sector since 2010
  • Figure 4: Psychiatry partnering by stage of development since 2010
  • Figure 5: Psychiatry partnering by technology type since 2010
  • Figure 6: Psychiatry partnering by indication since 2010
  • Figure 7: Psychiatry deals with a headline value
  • Figure 8: Psychiatry deals with upfront payment values
  • Figure 9: Psychiatry deals with milestone payment
  • Figure 10: Psychiatry deals with royalty rates
  • Figure 11: Active Psychiatry dealmaking activity- 2010 to 2016
  • Figure 12: Top Psychiatry deals by value since 2010
Back to Top